Estrella Immunopharma, Inc. (ESLA) vs Marker Therapeutics, Inc. (MRKR)
A side-by-side comparison of Estrella Immunopharma, Inc. and Marker Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ESLA
Estrella Immunopharma, Inc.
$0.43HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
MRKR
Marker Therapeutics, Inc.
$1.01HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — ESLA vs MRKR
growth of $100 · dividends reinvested · last 5yESLA -95.5% (-46.2%/yr)MRKR -94.1% (-43.2%/yr)MRKR compounded faster over this window
ESLA MRKR
ESLA vs MRKR: by the numbers
- •ESLA is the larger company ($18M vs $17M market cap).
- •Both run net losses; ESLA's is the smaller (0.00% vs -706.23% net margin).
Metrics side by side
Valuation
| Metric | ESLA | MRKR |
|---|---|---|
| P/S ratio | N/A | 13.66 |
| P/B ratio | N/A | 1.38 |
Profitability
| Metric | ESLA | MRKR |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | -706.23% |
| ROE | N/A | -71.57% |
| ROIC | N/A | -88.07% |
Growth (annualized)
| Metric | ESLA | MRKR |
|---|---|---|
| Total return CAGR (5Y) | -46.34% | -42.13% |
Frequently asked
- How have ESLA and MRKR total returns compared?
- Over the past 5 years, ESLA delivered -46.34% and MRKR delivered -42.13% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.